



FOR IMMEDIATE RELEASE

Contact: Ronald Trahan, +1-508-359-4005, x108, rtrahan@ronaldtrahan.com

FEops elects Rob Michiels as Chairman

Former CardiAQ Valve Technologies CEO and CoreValve COO says FEops' "predictive procedure-planning platform" may be crucial to the ultimate-outcome success of transcatheter-based valve therapies

"Certainly, Rob Michiels is one of the most experienced, most successful executives in the cardiovascular industry."

Matthieu De Beule, PhD, CEO, FEops

GENT, Belgium, Sept. 16, 2016 — **FEops**, which is developing "future-generation planning technology for transcatheter valve therapies", today announced that it has elected **Rob Michiels** to serve as Chairman of the Board of Directors, effectively immediately. Until September 2015, Michiels was Chief Executive Officer at **CardiAQ Valve Technologies**, the Transcatheter Mitral Valve Replacement (TMVR) company, which was acquired by **Edwards Lifesciences**.

(Click here for [Press Kit](#). Click here for [Video](#).)

"The participation of Rob Michiels underscores the disruptive and considerable opportunity for FEops to become the game-changer in the way interventional cardiovascular procedures are planned in the future," said **Dr. Matthieu De Beule**, FEops CEO and Founder.

"A fast-growing number of patients undergoing transcatheter valve procedures could significantly benefit from FEops' patient-based planning approach," said **Marc Lambrechts** (interim-chairman of FEops since December 2014, senior investment manager at Capricorn Venture Partners). "The addition of Rob Michiels to our oversight team is a tremendous endorsement of our technology platform. Because of his hands-on development experience in the percutaneous aortic and mitral valve replacement sectors, and his long track record of success in the cardiovascular device industry, Rob will be of great value to FEops' strategic direction."

"In terms of FEops' technology approach and market opportunity, I see a very strong correlation to my recent experiences at CoreValve and CardiAQ," said **Rob Michiels**. "Ultimately, there is no doubt in my mind that, in the near future, all definitive heart valve therapy treatment will shift toward less-invasive approaches, and I believe that FEops is uniquely positioned to offer all these implant technologies the necessary guide to further improve safety and efficacy."

About FEops

Privately held FEops, headquartered in Gent, Belgium, has developed a proprietary system for transcatheter valve procedure-planning based on patient-based computer simulations. Their first product, TAVIguide™, is currently the only CE-marked technology on the market, predicting how a TAVI implant will interact with the patient-specific aortic anatomy and thus providing insights in the optimal device size and position. Dedicated planning tools for other transcatheter valve procedures are in the pipeline.

-END-